Related Experiment Video
Updated: May 1, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Oncofetal protein IMP3, a new cancer biomarker
Yuna Gong1, Bruce A Woda, Zhong Jiang
1Department of Pathology, University of Massachusetts Medical School, Worcester, MA.
Abstract:
IMP3 is a member of a family of RNA-binding proteins that consists of IMP1, IMP2 and IMP3. These proteins contain 2 RNA recognition motifs and 4 K-homology domains that allow them to bind RNAs strongly and specifically. IMP3 is an oncofetal protein involved in embryogenesis and its expression is associated with a number of malignant neoplasms. IMP3 is associated with aggressive and advanced cancers and is specifically expressed in malignant tumors but is not found in adjacent benign tissues. Moreover, in vitro studies have shown that IMP3 promotes tumor cell proliferation, adhesion, and invasion. This review focuses on the studies of IMP3 expression in different cancers and emphasizes the potential utility of IMP3 in routine surgical pathology practice. We also discuss IMP3 as a prognostic biomarker for cancer patients' outcomes.
Insights
Insulinoma-associated protein 3 (IMP3) is an oncofetal protein linked to aggressive cancers. Its specific expression in tumors suggests potential as a diagnostic and prognostic biomarker in surgical pathology.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Insulinoma-associated protein 3 (IMP3) is an RNA-binding protein crucial in embryogenesis.
- IMP3 expression is significantly elevated in various malignant neoplasms compared to benign tissues.
- Its structural features, including RNA recognition motifs and K-homology domains, enable specific RNA binding.
Purpose of the Study:
- To review the role of IMP3 expression in different cancer types.
- To highlight the potential of IMP3 as a biomarker in surgical pathology.
- To discuss IMP3's utility as a prognostic indicator for patient outcomes.
Main Methods:
- Literature review of studies investigating IMP3 expression in cancers.
- Analysis of in vitro data on IMP3's functional role in tumor cells.
- Evaluation of IMP3's association with cancer aggressiveness and patient prognosis.
Main Results:
- IMP3 is specifically expressed in malignant tumors, absent in adjacent normal tissues.
- In vitro studies demonstrate IMP3 promotes tumor cell proliferation, adhesion, and invasion.
- Elevated IMP3 expression correlates with aggressive and advanced cancer stages.
Conclusions:
- IMP3 is a valuable biomarker for distinguishing malignant from benign tissues.
- IMP3 shows significant potential for routine use in surgical pathology.
- IMP3 serves as a promising prognostic biomarker for predicting cancer patient outcomes.
